Advertisement
Screener

Achieve Life Sciences, Inc. (ACHV) Reimbursement Revenue (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

Achieve Life Sciences, Inc. Reimbursement Revenue (Deprecated 2018-01-31)

Achieve Life Sciences, Inc. (ACHV) reported Reimbursement Revenue (Deprecated 2018-01-31) of $5.06 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.

Discontinued › Income Statement › Other Income

us-gaap:ReimbursementRevenue · last filed 2017-07-31

  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2016-06-30 was $2.12M, a 47.28% decline year-over-year.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $2.94M, a 113.97% increase year-over-year.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for fiscal 2016 was $5.06M, a 72.13% decline from fiscal 2015.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for fiscal 2015 was $18.16M, a 33.03% decline from fiscal 2014.
  • Achieve Life Sciences, Inc. reimbursement revenue (deprecated 2018-01-31) for fiscal 2014 was $27.12M.
Period endReimbursement Revenue (Deprecated 2018-01-31) 3 monthReimbursement Revenue (Deprecated 2018-01-31) 6 monthReimbursement Revenue (Deprecated 2018-01-31) 9 monthReimbursement Revenue (Deprecated 2018-01-31) 12 month
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23
$0.00
derived: sum of 2 quarters · filed 2017-02-23
$2.12M
derived: sum of 3 quarters · filed 2017-07-31
$5.06M
10-K · filed 2017-02-23
2016-09-30$0.00
10-Q · filed 2016-11-10
$2.12M
derived: sum of 2 quarters · filed 2017-07-31
$5.06M
10-Q · filed 2016-11-10
$11.09M
derived: sum of 4 quarters · filed 2017-07-31
2016-06-30$2.12M
10-Q · filed 2017-07-31
$5.06M
10-Q · filed 2017-07-31
$11.09M
derived: sum of 3 quarters · filed 2017-07-31
$17.82M
derived: sum of 4 quarters · filed 2017-07-31
2016-03-31$2.94M
10-Q · filed 2017-05-15
$8.96M
derived: sum of 2 quarters · filed 2017-05-15
$15.70M
derived: sum of 3 quarters · filed 2017-05-15
$19.73M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$6.02M
10-K · filed 2017-02-23
$12.76M
derived: sum of 2 quarters · filed 2017-02-23
$16.79M
derived: sum of 3 quarters · filed 2017-02-23
$18.16M
10-K · filed 2017-02-23
2015-09-30$6.74M
10-K · filed 2017-02-23
$10.76M
derived: sum of 2 quarters · filed 2017-02-23
$12.14M
10-Q · filed 2016-11-10
2015-06-30$4.03M
10-K · filed 2017-02-23
$5.40M
10-Q · filed 2016-08-04
2015-03-31$1.37M
10-K · filed 2017-02-23
2014-12-31$27.12M
10-K · filed 2017-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92